3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uveal Melanoma
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors, Adult
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Ipilimumab
10
Nivolumab
9
Interleukin-2
5
Cyclophosphamide
5
pembrolizumab
3
incomplete Freund's adjuvant
3
fludarabine phosphate
3
Radiosurgery
3
Melphalan
3
ADI PEG20
3
sotrastaurin
2
fludarabine
2
Specimen Handling
2
Ranibizumab
2
Magnetic Resonance Spectroscopy
2
MART-1 Antigen
2
CTLA-4 Antigen
2
Biopsy
2
utomilumab
1
tocilizumab
1
siremadlin
1
sargramostim
1
ruxolitinib
1
relatlimab
1
pentetreotide
1
obinutuzumab
1
montanide ISA 51
1
lifileucel
1
gp100 Melanoma Antigen
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Uveal Melanoma
×
Toll-Like Receptor 1
×
Clear all
NCT05576077
2025-03-10
STARLING
Turnstone Biologics, Corp.
Phase 1
Terminated
31 enrolled